We are currently experiencing technical difficulties with our search function. We are working on resolving the issue. Please try again later.
This search looks for keywords in all of the website’s content. Search tips
Filter by
- Agenda(0)
- Annex to CHMP highlights(0)
- Annual Report(0)
- Application withdrawal assessment report(0)
- Committee meeting report(0)
- COVID-19 vaccine safety update(0)
- Direct healthcare professional communication(0)
- EPAR - All authorised presentations(0)
- EPAR - Amended Product Information(0)
- EPAR - Assessment report - Variation(0)
- EPAR - Assessment report on maintenance of orphan designation - Initial authorisation(0)
- EPAR - Assessment report on maintenance of orphan designation - Post-authorisation(0)
- EPAR - Conditions imposed on member states for safe and effective use(0)
- EPAR - Overview(0)
- EPAR - Paediatric investigation plan compliance statement(0)
- EPAR - Procedural steps taken and scientific information after authorisation(0)
- EPAR - Procedural steps taken before authorisation(0)
- EPAR - Product Information(0)
- EPAR - Public assessment report(0)
- EPAR - Risk-management-plan summary(0)
- EPAR - Scientific conclusion(0)
- EPAR - Scientific Discussion(0)
- EPAR - Scientific Discussion - Variation(0)
- EPAR - Steps taken after authorisation when a cutoff date has been used(0)
- Herbal - Call for data(0)
- Herbal - Herbal monograph(0)
- Herbal - HMPC assessment report(0)
- Herbal - HMPC opinion on a European Union herbal monograph(0)
- Herbal - List of references supporting the assessment report(0)
- Herbal - Overview of comments received during consultation(0)
- Herbal - Summary of assessment report for the public(0)
- Herbal – European Union herbal monograph(0)
- Herbal – European Union list entry(0)
- Leaflet(0)
- Maximum Residue Limits - Divergent opinion(0)
- Maximum Residue Limits - Opinion(0)
- Maximum Residue Limits - Report(0)
- Maximum Residue Limits - Summary of opinion(0)
- Medicine QA(0)
- Medicines under additional monitoring(0)
- Minutes(0)
- Newsletter(0)
- Opinion outside EU - All presentations(0)
- Opinion outside EU - Assessment report - Variation(0)
- Opinion outside EU - Medicine questions and answers(0)
- Opinion outside EU - Procedural steps taken and scientific information after opinion(0)
- Opinion outside EU - Procedural steps taken before opinion(0)
- Opinion outside EU - Product information(0)
- Opinion outside EU - Public assessment report(0)
- Opinion outside EU - Risk-management-plan summary(0)
- Opinion outside EU - Scientific discussion(0)
- Opinion outside EU - Summary for the public(0)
- Opinion outside EU - Summary of opinion(0)
- Opinion outside EU - Summary of opinion - Initial authorisation(0)
- Opinion outside EU - Withdrawal assessment report(0)
- Orphan designation(0)
- Orphan review(0)
- Other(0)
- Overview of comments(0)
- Parallel distribution(0)
- Periodic safety update single assessment(0)
- PIP - Notification of discontinuation of a paediatric development which is covered by an agreed PIP decision(0)
- PIP - Paediatric-investigation-plan summary(0)
- PIP decision(0)
- Position statement(0)
- PRAC recommendation on signal(0)
- Presentation(0)
- Press Release(0)
- Procurement(0)
- Public Statement(0)
- Recommendation on medication errors(0)
- Recruitment(0)
- Referrals document(0)
- Regulatory and procedural guideline(0)
- Report(0)
- Scientific guideline(0)
- Standard Operating Procedure - SOP(0)
- Summary of opinion(0)
- Summary of opinion - Initial authorisation(0)
- Supply shortage(0)
- Template or form(0)
- Withdrawal letter(0)
- Work Instruction - WIN(0)
- Work programme(0)
- Advanced therapies(398)
- Antimicrobial resistance(46)
- Biologicals(24)
- Biosimilars(151)
- Brexit(30)
- Careers(3)
- Clinical trials(181)
- Compassionate use(4)
- Compliance and inspections(105)
- Corporate(47)
- COVID-19(466)
- Data on medicines(166)
- Early access(25)
- Fees(12)
- Generic and hybrid medicines(398)
- Governance(91)
- Innovation(283)
- Maximum residue limit(17)
- Medication error(6)
- Medicines(7753)
- Medicines for use outside the EU(29)
- Medicine shortages(120)
- Mpox(17)
- Paediatrics(3078)
- Parallel distribution(6)
- Pharmacovigilance(2911)
- Procurement(9)
- Product information(61)
- Quality of medicines(84)
- Rare diseases(3275)
- Referrals(373)
- Regulatory and procedural guidance(551)
- Research and development(228)
- Scientific advice(37)
- Scientific guidelines(1013)
- SME(62)
- Vaccines(381)
- Veterinary limited markets(15)
Search results (24261)
turkey herpes virus, strain FC-126, expressing infectious bursal disease virus VP2 protein, live
Last updated:
MedicineVeterinaryAuthorised
Decision type:
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area:
Infectious diseasesVaccines
PIP number:
P/0139/2023
Route(s) of administration:
Intramuscular use
Pharmaceutical form(s):
Dispersion for injection
Decision date:
Last updated:
Compliance check:
✖
PIPHuman
The European Medicines Agency (EMA) makes upgrades to this website from time to time, to improve user experience. During these upgrades, the website is unavailable for a short period of time, outside of EMA working hours. This page lists when we are planning the next outage and the main improvements made.
Last updated:
Corporate
Decision type:
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area:
Infectious diseases
PIP number:
P/0118/2023
Route(s) of administration:
Intravenous use
Pharmaceutical form(s):
Concentrate for solution for infusion
Decision date:
Last updated:
Compliance check:
✖
PIPHuman
Online
European Medicines Agency, Amsterdam, the Netherlands
Live broadcast
Start date:
14 June 2024, 09:00 (CEST)
End date:
14 June 2024, 16:30 (CEST)
EventHumanData on medicines
Decision type:
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area:
Haematology-Hemostaseology
PIP number:
P/0151/2023
Route(s) of administration:
Intravenous use
Pharmaceutical form(s):
Solution for injection/infusion
Decision date:
Last updated:
Compliance check:
✖
PIPHuman
Decision type:
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area:
Infectious diseases
PIP number:
P/0119/2023
Route(s) of administration:
Intramuscular useIntravenous use
Pharmaceutical form(s):
Solution for injection
Decision date:
Last updated:
Compliance check:
✖
PIPHuman
Date of designation:
Expired
Last updated:
OrphanHuman
Date of designation:
Expired
Last updated:
OrphanHuman
sorafenib
Carcinoma, Hepatocellular
Carcinoma, Renal Cell
Date of authorisation:
Revision:
33
Last updated:
MedicineHumanAuthorised